相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Meletios Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
Donna M. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
Thierry Facon et al.
LANCET (2007)
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma:: A report from the GIMEMA -: Italian multiple myeloma network
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma:: Combination therapy improves time to progression
Robert Z. Orlowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma
Robert A. Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM)
P. Sonneveld et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study
Michele Cavo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A comparison of allografting with autografting for newly diagnosed myeloma
Benedetto Bruno et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy
A. K. Stewart et al.
LEUKEMIA (2007)
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Paul G. Richardson et al.
BLOOD (2006)
Maintenance, therapy with thalidomide improves survival in patients with multiple myeloma
Michel Attal et al.
BLOOD (2006)
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma:: results of a multicenter phase 1/2 study
Maria-Victoria Mateos et al.
BLOOD (2006)
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
F Garban et al.
BLOOD (2006)
Prevalence of monoclonal gammopathy of undetermined significance
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled-trial
A Palumbo et al.
LANCET (2006)
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321
B Barlogie et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the eastern cooperative oncology group
SV Rajkumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
SV Rajkumar et al.
BLOOD (2005)
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy:: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA
J Bladé et al.
BLOOD (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma
S Jagannath et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Drug therapy: Multiple myeloma
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Single versus double autologous stem-cell transplantation for multiple myeloma
M Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Treatment of plasma cell dyserasias with thalidomide and its derivatives
MA Dimopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
JA Child et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma
DG Maloney et al.
BLOOD (2003)
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies
RZ Orlowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
PG Richardson et al.
BLOOD (2002)
A long-term study of prognosis in monoclonal gammopathy of undetermined significance
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Multiple myeloma: An odyssey of discovery
RA Kyle
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Recovering DNA and optimizing PCR conditions from microdissected formalin-fixed and paraffin-embedded materials
ZP Ren et al.
PATHOBIOLOGY (2000)